afffundno abstract
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study2013· article· en· The Lancet Neurology· Biochemistry, Genetics and Molecular Biology
233
citations
Every work in the frame. Each row carries the routes that admitted it, because a frame that forgets how it found something cannot be audited.